Impact of Biofield Energy Treatment Based Test Formulation on Vital Organ Health Specific Biomarkers Using Cell Line Study

Journal: Journal of Tissue Repair and Regeneration PDF  Web

Published: 13-Jul-19 Volume: 1 Issue: 2

DOI: 10.14302/issn.2640-6403.jtrr-19-2946 ISSN: 2640-6403

Authors: Ariadne Esmene Afaganis, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak, Mayank Gangwar, Snehasis Jana

Citation: Ariadne Esmene Afaganis, Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Gopal Nayak et al. (2019) Impact of Biofield Energy Treatment Based Test Formulation on Vital Organ Health Specific Biomarkers Using Cell Line Study. Journal of Tissue Repair and Regeneration - 1(2):22-36.

  • 99 Views
  • Downloads

Abstract

Multiple organ dysfunction syndrome or failure is one of the major concerns against healthcare services in order to maintain the normal function. The present study aimed to explore the impact of the Biofield Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain using standard activity parameters in specific cell-based assays. The test formulation and cells medium was divided into two parts, one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Ariadne Esmene Afaganis, Canada and was labeled as the Biofield Treated (BT) test formulation/media. The test formulation was tested for cell viability, and the data suggested that the test formulation was found safe and non-toxic against all the cell lines. Cytoprotective activity among the experimental groups showed a significant improved activity by 94.4% at 1 µg/mL in untreated medium (UT-Med) + Biofield Treated Test Item (BT-TI) group in human cardiac fibroblasts cells (HCF) cells, while 84.4% at 10 µg/mL in BT-Med + BT-TI groups in human hepatoma cells (HepG2), and 124% increased cytoprotective action at 1 µg/mL in UT-Med + BT-TI group in adenocarcinomic human alveolar basal epithelial cells (A549) cells as compared with the untreated test group. ALP activity in MG-63 cells was significantly increased by 85.9% at 10 µg/mL in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 59.2% at 0.1 µg/mL in BT-Med + BT-TI groups as compared to the untreated group. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 53% and 40.5% at 1 and 10 µg/mL concentrations respectively, in UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 68.5%, 70.7%, and 16.8% at 0.1, 1, and 10 µg/mL respectively, and 86.5%, 62.5%, and 34.2% improved cellular protection at 0.1, 1, and 10 µg/mL respectively, in BT-Med + BT-TI group as compared to the untreated test group. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 33.5%, 63.2%, and 99.2% at 10 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by increased by 39.8% (at 10 µg/mL), 44% (at 25.5 µg/mL), and 59.7% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated group. Serotonin level was significantly increased by 59.2% (at 0.1 µg/mL), 190.3% (at 0.1 µg/mL), and 201% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 159.1% (at 50 µg/mL), 212.7% (at 1 µg/mL), and 278.3% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, the present data concluded that the overall multiple organ health using various standard biomarkers in specific cell lines were significantly improved with respect to health of bones, heart, liver, lungs, and brain after treatment with the Biofield Energy treated test formulation (The Trivedi Effect®). Thus, it can be used as a complementary and alternative therapy approach against many multiple organ disorders such as coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Conclusion

The experimental study outcomes showed that the test formulation treated with the Biofield Energy was found safe and non-toxic, which was tested using standard MTT cell viability assay in all the cell lines used for various activity. Cytoprotective activity was tested using human cardiac fibroblasts cells (HCF), which showed maximum restoration of cell viability by 94.4% at 1 µg/mL in UT-Med + BT-TI group, while in HepG2 cells the maximum restoration of cell viability was 84.4% at 10 µg/mL in the BT-Med + UT-TI group, and the test formulation in A549 cells showed maximum restoration of cell viability by 86.1% at 25 µg/mL in the BT-Med + BT-TI group as compared with the untreated test group. Similarly, ALP activity was significantly increased by 85.9%, 85.2%, and 87.4% at 10 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group in MG-63 cells, while 28%, and 59.2% increased ALP activity was found at 0.1 µg/mL in the BT-Med + UT-TI, BT-Med + BT-TI groups, respectively as compared to the untreated test groups in Ishikawa cells. Similarly, the LDH activity was decreased using increased percentage cellular protection data, which showed 53% and 40.5% increased protection at 1 and 10 µg/mL concentrations respectively in the UT-Med + BT-TI group, and 68.5%, 70.7%, and 16.8% improved cellular protection at 0.1, 1, and 10 µg/mL respectively in the BT-Med + UT-TI group, while 86.5%, 62.5%, and 34.2% improved cellular protection at 0.1, 1, and 10 µg/mL respectively, in BT-Med + BT-TI group as compared to the untreated test group. ALT activity was studied and data showed improved cellular protection of HepG2 cells (decreased of ALT activity) by 33.5%, 63.2%, and 99.2% at 10 µg/mL in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively as compared with the untreated test group. SOD activity was significantly increased in A549 (lungs) cells by 39.8% (at 10 µg/mL), 44% (at 25.5 µg/mL), and 59.7% (at 25.5 µg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively as compared with the untreated test group. Serotonin level was significantly increased in SH-SY5Y cells by 59.2% (at 0.1 µg/mL), 190.3% (at 0.1 µg/mL), and 201% (at 1 µg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively as compared with the untreated test group. However, VDR expression was tested in MG-63 cells, which showed increased RQ of VDR by 37.2% and 159.1% in the UT-Med + BT-TI group at 10 and 50 µg/mL respectively, while 190.7%, 212.7%, 190.3%, and 164.1% at 0.1, 1, 10, and 50 µg/mL respectively, in the BT-Med + UT-TI group, and increased RQ of VDR by 60.2%, 93.5%, 278.3%, and 215.6% at 0.1, 1, 10, and 50 µg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test control group. Overall, it can be concluded that the Biofield Energy based test formulation would be the best alternative treatment strategy for improved functioning of heart, liver, bones, neuronal, and lungs parameters against any oxidative stress or damage induced by free radicals. Thus, results suggested that Biofield Energy Treatment can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders such as stroke, thromboembolic disease, congestive heart failure, congenital heart disease, peripheral artery disease, rheumatic heart disease, valvular heart disease, and venous thrombosis, etc. Besides, it would also protect against many hepatic disorders (cirrhosis, liver cancer, hemochromatosis, Wilson disease), lungs disorders (asthma, chronic bronchitis, emphysema, cystic fibrosis, and pneumonia), and many immune system related disorders. In addition, this novel test formulation can also be utilized for organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immune-related disease conditions like Alzheimer’s Disease (AD), Ulcerative Colitis (UC), Dermatitis, Asthma, Irritable Bowel Syndrome (IBS), Hashimoto Thyroiditis, Multiple Sclerosis, Aplastic Anemia, Graves’ Disease, Diabetes, Parkinson’s Disease, Myasthenia Gravis, Atherosclerosis, etc. to improve overall health and Quality of Life.